Drugs / Pegol-Sihematide
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02619097 | Jun 2014 → Dec 2015 | anemia, myelodysplastic syndrome | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02586402 | Oct 2015 → Aug 2016 | anemia, chronic renal failure syndrome | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03903809 | Jun 2019 → Oct 2021 | chronic kidney disease | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03902691 | May 2019 → Feb 2021 | chronic kidney disease | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegol-sihematide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02619097 ↗ |
| Route | Intravenous | “multiple intravenous doses of pegol-Sihematide” NCT02586402 ↗ |